

CALMARE® FAQs

✓ **Where and when was the Scrambler Therapy™ technology developed?**

The technology known in clinical publications as Scrambler Therapy™ was developed by Professor Giuseppe Marineo in Rome, Italy. His research of chronic pain began over 24 years ago.

✓ **How many patients have been treated with the Calmare® Pain Therapy Treatment?**

Over 3,500 patients have been treated in Europe, and over 600 patients in the US.

✓ **What clinical indications have been treated with the Calmare® Pain Therapy Treatment?**

Neuropathic and oncologic pain. Severe chronic neuropathic pain non-responsive to pharmaceutical treatment, traditional TENS, or implanted devices.

✓ **What is the typical treatment protocol?**

Neuropathic and Oncologic Pain: The initial treatment protocol consists of 10-12 consecutive treatments of 30 to 45 minutes once a day (5 days a week for 2 weeks). Additional “booster treatments” may be needed.

✓ **Have there been treatment results with “no pain” periods of seven days or longer?**

Yes. In most cases, after the initial treatment protocol patients experience reduced or no pain. However, it is most important that the chronic pain is first properly diagnosed as neuropathic or oncologic and not musculoskeletal pain.

✓ **What is the longest recorded “no pain” period between treatments?**

The average recorded “no pain” period is 1 to 3 months, with 1 year being the longest interval without “booster treatments.” Patients who have had chronic pain for an extended period of time will most likely require “booster treatments”.

✓ **What is unique about treating cancer pain using Calmare® Pain Therapy Treatment?**

Unlike traditional TENS devices and some spinal cord stimulators, Calmare® Pain Therapy Treatment is effective in treating visceral oncologic pain and CIPN (chemotherapy-induced peripheral neuropathy).

The type of cancer or the stage of cancer may not allow for lengthy “no pain” periods. Frequency of “booster treatments” will depend on the specific needs of individual patients.

✓ **What known clinical indications are not receptive to treatment with Calmare® Pain Therapy?**

Acute pain and chronic pain that is diagnosed as musculoskeletal pain and not neuropathic pain. Additionally, “non receptive” refers to patients who do not experience pain relief or diminished pain after a treatment (or several treatments) or not possible to localize a specific pain site.

Also, pain caused from “active inflammation” that continuously damages the nerve fibers (connective tissue diseases, musculoskeletal pain devoid of neuropathic component and arthritis).

✓ **Is Calmare® Pain Therapy Treatment covered by health insurance and Medicare?**

On July 1, 2011 the AMA announced CPT 0278T (effective Jan. 1, 2012) to report Scrambler Therapy™. This does not guarantee that insurers will or will not cover Calmare®. At this time health coverage for Calmare® is determined on an individual basis. Some insurers have covered Calmare® treatments.



CALMARE® Pain Therapy Treatment is clinically proven to diminish recurrence of pain without the traditional side effects of drugs such as drowsiness, depression and addiction.

CALMARE® is indicated for:
Intractable Cancer Pain, Failed Back Surgery Syndrome, Sciatic and Lumbar Pain, Post-Herpetic Neuralgia, Brachial Plexus Pain, Peripheral Neuropathies, and Chronic Neuropathic Pain.



CALMARE® Pain Therapy Treatment:

- Non-invasive
 - Painless
 - Drug Free
 - No known side effects

A UNIQUE SOLUTION

The Calmare® Pain Therapy Treatment (Scrambler MC-5A) is an innovative non-invasive pain therapy treatment. The device is used to treat various types of chronic neuropathic, oncologic and drug-resistant pain. Unlike typical Class II drugs prescribed for pain management, the MC-5A does not just treat the symptoms of pain but is clinically proven to diminish recurrence without traditional side effects such as drowsiness, depression and addiction.

Calmare® Pain Therapy Treatment uses a bio-physical methodology rather than biochemical. During Calmare® treatments, pain is completely removed, in most cases, regardless of pain intensity. With subsequent treatments, pain recurs with diminishing intensity until it disappears in a high percentage of cases.



For more information contact:

Competitive Technologies, Inc.
5113 Piper Station Drive, Ste. 206
Charlotte, NC 28277

www.Calmarett.com
CalmareTT@CompetitiveTech.net
office: 704.544.5999
fax: 704.544.5976



CALMARE®

Pain Therapy Treatment

Featuring Scrambler Therapy™ Technology



FOR TREATMENT OF DRUG-RESISTANT
CHRONIC NEUROPATHIC AND CANCER PAIN